Vijaya Diagnostic Centre Ltd Q1 FY2027 Concall Summary

Key Takeaways

• Strong quarter, broad-based growth: Revenue rose 22.8% YoY on 16.5% test volume growth, with both radiology and pathology contributing and new hubs ramping ahead of plan.
• Operating leverage is kicking in: EBITDA margin expanded 360 bps YoY to 42.7% as mature clusters like Hyderabad grew 17% without adding hubs, while the drag from 10 new hubs was just ~0.5%.
• New markets are validating the model: Both Bangalore hubs broke even in their first year, and tier-2 locations like Rajahmundry hit breakeven in 9 months, well ahead of schedule.
• Wellness is becoming a material, disclosed driver: Pure wellness revenue reached 14.8% of the mix, up from ~8% pre-COVID, with tier-2 geographies now contributing meaningfully.
• What to watch next quarter: Whether the JP Nagar flagship hub in Bangalore accelerates that market's trajectory, the pace of Pune's growth as its large hub comes online, and any update on the pricing strategy reassessment promised post-Q2.

Growth Drivers & Cluster Economics

• Mature cluster still delivering: Hyderabad grew 17% YoY in Q1 without adding any hubs in the last couple of years, demonstrating the operating leverage embedded in a dense hub-and-spoke network.
• New hubs ramping faster than expected: The 10 hub centres commissioned in the prior year exceeded ramp-up expectations, with momentum continuing into their second year as pathology revenues now scale alongside radiology.
• Hub margin mechanics are favourable: 60–70% of a hub's cost is fixed, and most FY26 hubs have already achieved breakeven, so fixed costs are absorbed. With ~89% contribution margin, incremental pathology revenue flows directly to EBITDA, meaning no margin dip is expected from pathology scaling.
• Tier-2 locations outperforming: Locations like Rajahmundry, Tirupati, Khammam, and Krishna Nagar achieved breakeven in just 2 quarters in most cases. Rajahmundry broke even in 9 months versus an expected 3–4 months extra, with wellness packages drawing customers from a 150–200 km radius.
• Market share gains visible but unquantified: Existing spokes over 5 years vintage are growing at higher double digits, indicating a shift from unorganized to organized players. Management says quantifying exact market share is difficult and they "don't have those numbers handy."
• Integrated model drives wallet share: Vijaya's combined radiology-plus-pathology model yields 3.7 tests per patient and ~₹1,860 per patient versus ~₹900–₹950 for pure pathology peers, whose 25–30% B2B mix at discounted prices further widens the margin gap.

Suprita Reddy: "The pace at which most of these hubs have ramped up has exceeded our own expectations. The momentum has continued into the second year as well with pathology revenues now beginning to scale alongside the radiology. This strong execution has given us the confidence to deepen our presence in these new markets and replicate the expansion strategy demonstrated last year."

New Market Expansion

Bangalore & Karnataka

• Entry validated: Both initial hubs (HSR layout and Yelahanka) exceeded expectations and broke even in the first year itself.
• Flagship hub commissioned: A state-of-the-art hub at JP Nagar opened in July with ₹30 crores capex, featuring Bangalore's first 3 Tesla Omega MRI and a digital PET-CT with cardiac CT. It will serve as the central lab for the Bangalore network.
• Market structure favours the approach: No single brand has 30–40 centres in Bangalore. Locality-specific chains with 5–6 centres are the norm, partly due to traffic and logistics constraints, creating an opening for a dense cluster strategy.
• Sequencing is deliberate: Once the JP Nagar lab settles and gets accredited, more hubs and spokes will follow, then home collection will start. Management is "setting up Bangalore for the next 5-year journey."

Pune

• Steady growth: Revenue moved from ~₹10.8 crores to ₹12.8 crores, delivering 18% YoY growth.
• Capacity constraint being addressed: A fully automated, state-of-the-art hub centre will come up in Pune this financial year to address back-end constraints of existing PH centres, enabling more spokes, collection centres, wellness, and home collection.
• Growth trajectory will differ: Management expects Pune to show "inching towards the growth" after the large hub is operational, but it will grow "a little bit differently" compared to eastern India, Karnataka, and rest of AP/Telangana.

Competitive dynamics

• Hyderabad moat is real: The second and third largest diagnostic players in Hyderabad are deploying capital outside the city because Vijaya already holds greater market share. No strong competitive intensity in network expansion from organized players in Hyderabad and rest of AP/Telangana. [15–16]
• Vizag build-out underway: One spoke added, with more spokes coming in the next couple of months. Competition is not matching Vijaya's network expansion intensity.

Suprita Reddy: "Definitely. Bangalore and Hyderabad are very correlated to each other especially because I would say the southern part of India... If you say what do you look at for Vijaya in the next 10 to 15 years it's going to be definitely eastern part of India and Karnataka. Both of these are probably enough for the next 7- to 8-year plan to go as deep as Hyderabad. And these 3 states will definitely give us the numbers that all of us would be looking at."

Wellness

• Scale and mix: Pure wellness revenue reached 14.8% of the total, up from ~8% pre-COVID. Management emphasized this is "pure wellness revenue coming in from customers who are wanting to come and avail one of these packages."
• Tier-2 contribution is a surprise: Tier-2 geographies are now contributing to wellness revenue, which was not the case earlier. Awareness, migration, and education in tier-2 are driving this, and the trend has been stronger than expected.
• Package evolution extends the funnel: Offerings now span from basic urine and blood investigations up to whole-body imaging (MR, CT), enabled by newer hub centres getting advanced cardiac CTs. This allows premium multi-organ screening packages.
• Realization tailwind: With improving share of wellness, patient-level and test-level realization is expected to inch upwards.
• Strategy is portable: The premium wellness packaging approach developed in Hyderabad will be taken forward into Bengaluru, Pune, and other geographies.

Margins

• Operating leverage in action: EBITDA margin improved to 42.5%. The mature Hyderabad cluster growing at 17% was the primary driver, while the drag from 10 new hubs was only ~0.5%.
• Hub cost structure is the engine: With 60–70% of hub costs fixed and most FY26 hubs already at breakeven, the ~89% contribution margin on incremental pathology revenue means future volume growth drops straight to EBITDA.
• FY27 expansion is staggered, not lumpy: Unlike Q1 FY26 when 6 hubs launched at once, capex in FY27 will be phased. Management expects no significant margin impact during the current year or any single quarter.
• Confidence in the floor: Management is "fairly confident of achieving above 40% EBITDA margin" even with a 1–1.5% drag from future expansion.

Capital Allocation & Network Build-out

• FY27 capex plan: ₹190–195 crores total, covering 9 hub centres, 10–12 spoke centres, and the Panjagutta reference laboratory.
• Hub capex breakdown: JP Nagar Bengaluru at ~₹30 crores; the balance 8 hubs at ₹15–16 crores each. The reference lab capex is included in the overall ₹190 crores figure.
• Land acquisition in AP medical hub: ₹8–10 crores allocated to acquire land in a key AP medical hub for a future state-of-the-art hub centre. Management has been trying to open a centre in this location for 6–7 years.
• Tier-2 land purchase under consideration: Inspired by Rajahmundry's outperformance, management is considering buying land in another tier-2 geography to create a similar state-of-the-art hub.
• Network expansion cadence (next 12 months): 9 hubs planned this year, with 6 of the 9 across the three new metro markets (Pune, Bangalore, Kolkata). Combined with last year's ~9 hubs, that will total 15 hub centres across these three metros.
• Pune hub pipeline: Two more hub centres and additional spokes planned in the coming 12 months.

Suprita Reddy: "This is an area where we've been trying to open a centre for the last almost 6 to 7 years. So when we found this piece of land which is ideal in size and also in terms of location is located in the medical hub of that particular region we said it makes so it's one of its kind but it's going to be a state-of-the-art hub centre for Andhra."

Data & AI

• Data monetization is on the radar but unshaped: Management acknowledges holding "a goldmine of data" but does not yet know the compliance boundaries on what can and cannot be done. They plan to engage the right agencies and then chart a path. As of today, data is not shared with anyone.

Suprita Reddy: "Kartick, we are on the same page as you. We have a goldmine of data. But today we do not know in terms of compliance on what can be done, cannot be done. We will engage the right agencies and after we get what is required as per compliance, probably plan it out accordingly."

Guidance & Commitments

Key Metrics